BR0113101A - Utilização de um inibidor de lìpases e processo e medicamento oral para tratamento, redução ou prevenção de dispepsia funcional - Google Patents

Utilização de um inibidor de lìpases e processo e medicamento oral para tratamento, redução ou prevenção de dispepsia funcional

Info

Publication number
BR0113101A
BR0113101A BR0113101-0A BR0113101A BR0113101A BR 0113101 A BR0113101 A BR 0113101A BR 0113101 A BR0113101 A BR 0113101A BR 0113101 A BR0113101 A BR 0113101A
Authority
BR
Brazil
Prior art keywords
lipase inhibitor
medicament
treating
reducing
functional dyspepsia
Prior art date
Application number
BR0113101-0A
Other languages
English (en)
Inventor
Christine Feinle
Michael Fried
Thomas Rades
Hans Lengsfeld
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0113101A publication Critical patent/BR0113101A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"UTILIZAçãO DE UM INIBIDOR DE LIPASES E PROCESSO E MEDICAMENTO ORAL PARA TRATAMENTO, REDUçãO OU PREVENçãO DE DISPEPSIA FUNCIONAL". A presente invenção refere-se ao uso de inibidores de lípases, por exemplo, orlistat, para a manufatura de medicamentos para o tratamento, redução ou prevenção de dispepsia funcional, por exemplo, intensidade de plenitude do estómago, náuseas, dilatação depois da ingestão de pequenas ou grandes refeições, especialmente refeições que contêm gorduras ou ricas em gorduras, e medicamentos assim manufaturados.
BR0113101-0A 2000-08-09 2001-07-28 Utilização de um inibidor de lìpases e processo e medicamento oral para tratamento, redução ou prevenção de dispepsia funcional BR0113101A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00117088 2000-08-09
PCT/EP2001/008776 WO2002011719A2 (en) 2000-08-09 2001-07-28 Lipase inhibitors for the treatment of dyspepsia

Publications (1)

Publication Number Publication Date
BR0113101A true BR0113101A (pt) 2003-06-24

Family

ID=8169476

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113101-0A BR0113101A (pt) 2000-08-09 2001-07-28 Utilização de um inibidor de lìpases e processo e medicamento oral para tratamento, redução ou prevenção de dispepsia funcional

Country Status (17)

Country Link
US (1) US6534539B2 (pt)
EP (1) EP1311260B1 (pt)
JP (2) JP4727901B2 (pt)
KR (1) KR100494245B1 (pt)
CN (1) CN1323661C (pt)
AR (1) AR030132A1 (pt)
AT (1) ATE390920T1 (pt)
AU (2) AU2002212120B2 (pt)
BR (1) BR0113101A (pt)
CA (1) CA2417607C (pt)
DE (1) DE60133470T2 (pt)
DK (1) DK1311260T3 (pt)
ES (1) ES2304132T3 (pt)
MX (1) MXPA03001182A (pt)
PT (1) PT1311260E (pt)
WO (1) WO2002011719A2 (pt)
ZA (1) ZA200300845B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1803714A1 (en) * 2005-12-27 2007-07-04 KRKA, tovarna zdravil, d.d., Novo mesto Process for preparing crystalline forms of orlistat
WO2010042499A1 (en) * 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
US20140116916A1 (en) * 2012-10-31 2014-05-01 2294719 Ontario Limited Therapy for Constipation
WO2014104871A1 (en) * 2012-12-24 2014-07-03 N.V. Nutricia Method for improving postprandial fat digestion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
TR200100472T2 (tr) 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri ile sitozan içeren farmasötik bileşimler
WO2000009122A1 (en) 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors

Also Published As

Publication number Publication date
MXPA03001182A (es) 2003-06-30
KR100494245B1 (ko) 2005-06-13
CN1323661C (zh) 2007-07-04
JP2004505914A (ja) 2004-02-26
JP4850821B2 (ja) 2012-01-11
KR20030029811A (ko) 2003-04-16
JP2008120821A (ja) 2008-05-29
DK1311260T3 (da) 2008-06-23
WO2002011719A3 (en) 2002-06-20
CN1446087A (zh) 2003-10-01
ZA200300845B (en) 2004-04-30
US6534539B2 (en) 2003-03-18
WO2002011719A2 (en) 2002-02-14
ES2304132T3 (es) 2008-09-16
AU2002212120B2 (en) 2006-05-11
US20020040049A1 (en) 2002-04-04
PT1311260E (pt) 2008-05-02
CA2417607C (en) 2008-01-29
EP1311260B1 (en) 2008-04-02
JP4727901B2 (ja) 2011-07-20
DE60133470T2 (de) 2009-05-07
EP1311260A2 (en) 2003-05-21
DE60133470D1 (de) 2008-05-15
ATE390920T1 (de) 2008-04-15
CA2417607A1 (en) 2002-02-14
AU1212002A (en) 2002-02-18
AR030132A1 (es) 2003-08-13

Similar Documents

Publication Publication Date Title
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
ES2150022T3 (es) Aerosol farmaceutico que contiene al menos un azucar.
KR950703968A (ko) 외상 손상과 관련된 신경학적 병변의 치료에서 카르바마제핀 및 옥스카르바제핀의 적용(application of carbamazepine and oxcarbazepine in the treatment of neurological lesions related to traumatic injuries)
DK1289517T3 (da) Farmaceutiske sammensætninger indeholdende cannabidiolderivater
BR0112685A (pt) Composição nutricional
NO20024011L (no) Karbohydratformulering (prebiotisk hjelpemiddel) for å forbedre immunforsvaret
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
PT914110E (pt) Metodo de modulacao da micro-circulacao
NO952906L (no) Farmasöytisk formulering for behandling av nikotinavhengighet
AU1935788A (en) A process for producing an administration and/or dosage form for medically active ingredients of drugs
BR9916114A (pt) Uso de apomorfina na fabricação de um medicamento para tratamento de disfunção erétil orgânica masculina
KR970061244A (ko) 치매 치료용 약학 조성물
AU5170499A (en) Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis
BR0113101A (pt) Utilização de um inibidor de lìpases e processo e medicamento oral para tratamento, redução ou prevenção de dispepsia funcional
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
ES2096207T3 (es) Prevencion y tratamiento de aterosclerosis.
BR0017329A (pt) Formulção farmacêutica de um medicamento, uso de melatonina na fabricação de um medicamento, e, método para prevenção ou tratamento de sintomas de discinesia tardia em um paciente usanto tal medicamento
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
BR0115611A (pt) Derivados de ciclohexano substituìdos e seu uso em medicamentos para tratamento de doenças cardiovasculares
NO20003510L (no) Fett-bindende polymerer
BR0207124A (pt) uso de alimta, pacote terapêutico para dispensação a,ou uso na dispensação a, um paciente sendo tratado para hcmv, e, artigo de manufatura
HUP9803039A2 (hu) Az elhízás kezelésére, megelőzésére, szövődményei kialakulásának kivédésére, a kialakult szövődmények kezelésére szolgáló gyógyászati kompozíció
BRPI0410507A (pt) combinação de substáncias ativas, uso de uma combinação de substáncias e processo para o tratamento do abuso do álcool e/ou da dependência de álcool
GB8928609D0 (en) Pharmaceutical composition
UA9672A (uk) Спосіб лікування деструктивних форм гострого панкреатиту

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.